Brokerages Set Sight Sciences, Inc. (NASDAQ:SGHT) Price Target at $4.68

Shares of Sight Sciences, Inc. (NASDAQ:SGHT - Get Free Report) have been given a consensus recommendation of "Hold" by the seven research firms that are covering the company, Marketbeat Ratings reports. Five investment analysts have rated the stock with a hold rating and two have issued a buy rating on the company. The average 1-year price target among analysts that have issued ratings on the stock in the last year is $4.68.

Several equities research analysts have recently commented on SGHT shares. Needham & Company LLC reiterated a "hold" rating on shares of Sight Sciences in a research note on Tuesday, January 14th. Piper Sandler reiterated a "neutral" rating and set a $5.50 price objective (down from $6.00) on shares of Sight Sciences in a research note on Friday, November 8th. Morgan Stanley lowered their price objective on shares of Sight Sciences from $7.00 to $5.00 and set an "equal weight" rating for the company in a research note on Monday, November 11th. Stifel Nicolaus lowered their price objective on shares of Sight Sciences from $6.00 to $5.00 and set a "buy" rating for the company in a research note on Thursday, February 6th. Finally, Lake Street Capital lowered their price objective on shares of Sight Sciences from $5.00 to $3.00 and set a "hold" rating for the company in a research note on Wednesday, January 15th.

Sight Sciences Stock Down 8.3 %

SGHT traded down $0.23 during trading on Wednesday, hitting $2.53. The stock had a trading volume of 467,590 shares, compared to its average volume of 231,282. The company has a market capitalization of $128.42 million, a PE ratio of -2.48 and a beta of 2.52. Sight Sciences has a twelve month low of $2.50 and a twelve month high of $8.45. The company has a debt-to-equity ratio of 0.36, a quick ratio of 9.74 and a current ratio of 10.18. The stock has a 50 day simple moving average of $3.12 and a two-hundred day simple moving average of $4.66.

Insider Activity at Sight Sciences

In other Sight Sciences news, CEO Paul Badawi sold 12,236 shares of Sight Sciences stock in a transaction on Thursday, January 2nd. The shares were sold at an average price of $3.60, for a total value of $44,049.60. Following the completion of the transaction, the chief executive officer now owns 5,713,197 shares of the company's stock, valued at approximately $20,567,509.20. The trade was a 0.21 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Over the last three months, insiders acquired 13,000 shares of company stock worth $50,832 and sold 63,014 shares worth $197,295. 28.90% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. KCK LTD. purchased a new position in Sight Sciences in the fourth quarter valued at $15,925,000. Barclays PLC increased its stake in shares of Sight Sciences by 317.4% during the third quarter. Barclays PLC now owns 50,300 shares of the company's stock worth $317,000 after purchasing an additional 38,248 shares in the last quarter. Millrace Asset Group Inc. purchased a new stake in shares of Sight Sciences during the third quarter worth about $874,000. Geode Capital Management LLC increased its stake in shares of Sight Sciences by 1.6% during the third quarter. Geode Capital Management LLC now owns 784,129 shares of the company's stock worth $4,941,000 after purchasing an additional 12,709 shares in the last quarter. Finally, State Street Corp increased its stake in shares of Sight Sciences by 17.4% during the third quarter. State Street Corp now owns 646,776 shares of the company's stock worth $4,075,000 after purchasing an additional 95,843 shares in the last quarter. Hedge funds and other institutional investors own 55.51% of the company's stock.

Sight Sciences Company Profile

Sight Sciences, Inc, an ophthalmic medical device company, engages in the development and commercialization of surgical and nonsurgical technologies for the treatment of eye diseases. It operates through two segments, Surgical Glaucoma and Dry Eye. The company's products include OMNI Surgical System, an implant-free glaucoma surgery technology indicated to reduce intraocular pressure in adult patients with primary open-angle glaucoma; and SION Surgical Instrument, a manually operated device used in ophthalmic surgical procedures to excise trabecular meshwork.